Potential advantages of novel antithrombotic agents administered conjunctively during coronary fibrinolysis.
Abendschein
D R
DR
Cardiovascular Division, Washington University School of Medicine, St. Louis, Missouri 63110, USA.
D001779:Blood Coagulation Factors / Q000502:physiology; D003327:Coronary Disease / Q000097:blood / Q000188:drug therapy*; D005342:Fibrinolysis; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D011516:Prothrombin / Q000502:physiology; D013925:Thromboplastin / Q000502:physiology; D014654:Vascular Patency
D001779:Blood Coagulation Factors; D005343:Fibrinolytic Agents; D011516:Prothrombin; D013925:Thromboplastin